NASDAQ:FULC | Free Cash Flow | Fulcrum Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2018-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$18.75M$8,000.00-$18.76M
2025-12-31-$16.8M$159,000.00-$16.96M
2025-03-31-$15.26M$0.00-$15.26M
2024-12-31-$16.76M$231,000.00-$16.99M
2024-03-31-$25.28M$28,000.00-$25.31M
2023-12-31-$23.16M$77,000.00-$23.24M
2023-03-31-$24.12M$171,000.00-$24.29M
2022-12-31-$19.7M$116,000.00-$19.81M
2022-03-31-$22.11M$246,000.00-$22.35M
2021-12-31-$21.86M$519,000.00-$22.38M
2021-03-31-$16.23M$262,000.00-$16.49M
2020-12-31-$19.83M$472,000.00-$20.3M
2020-03-31-$15.2M$567,000.00-$15.77M
2019-12-31-$4.5M$108,000.00-$4.6M
2019-03-31-$9.9M$310,000.00-$10.21M
2018-12-31-$6.4M$3.47M-$9.87M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$60.07M$314,000.00-$60.38M
2024-12-31-$2.22M$278,000.00-$2.5M
2023-12-31-$90.97M$508,000.00-$91.47M
2022-12-31-$97.05M$1.96M-$99.01M
2021-12-31-$78.48M$1.71M-$80.19M
2020-12-31-$53.66M$1.34M-$55M
2019-12-31-$39.48M$853,000.00-$40.34M
2018-12-31-$22.56M$8.98M-$31.54M